Barry Upton has more than 30 years of experience within Waters and has had roles in sales, sales management and business development. In his current role as Strategic Program Director, he works closely with our global customers to try to understand their challenges and then works with the different parts of the Waters organization to help them develop and introduce new technologies to our customers and to the Waters sales teams.
At Chiesi Group’s Chippenham laboratory in the UK, Waters’ UPLC systems with mass detection and informatics keep the team at the forefront of inhalation drug delivery products.
Learn how the ACQUITY QDa Mass Detector brings the power of mass detection for purification to Medicilon, helping this CRO meet the growing demand for outsourced services in the pharmaceutical and biotechnology industries.
In Japan, Professor Masanori Kataoka finds that the ACQUITY QDa Mass Detector is suitable for the synthesis and analysis of oligonucleotides – and sees ways to expand its use.